XpresSpa Group Signs Contract with Metropolitan Washington Airports Authority for XpresCheck™ COVID-19 Testing Facilities at Dulles International Airport and Reagan National Airport
Both Locations Expected to Commence Operations by Mid-March
WASHINGTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has signed a contract with Metropolitan Washington Airports Authority for XpresCheck™ COVID-19 Testing Facilities at Dulles International Airport and Reagan National Airport. Both of these locations are expected to be fully operational by mid-March.
At Dulles International Airport, XpresCheck will be building a pop-up facility located in the Main International Terminal, pre-security. This facility will host nine separate testing rooms with an anticipated capacity to administer over 500 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test.
At Reagan National Airport, XpresCheck will be building a pop-up facility in their existing XpresSpa location at National Hall, pre-security. This facility will host four separate testing rooms with an anticipated capacity to administer over 300 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test.
Doug Satzman, XpresSpa CEO, stated, "We are excited to be expanding XpresCheck to the metro Washington DC region by opening at both Dulles International and Reagan National next month. We recognize the important role our COVID-19 testing facilities play in supporting domestic and international air travel by ensuring airport employees and travelers feel safe and confident when traveling through our nation’s capital.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at eight locations in six airports: Denver International Airport, JFK International Airport, Boston Logan International Airport (2), Newark Liberty International Airport (2), Phoenix Sky Harbor International Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit:
Twitter: @xprescheck and Instagram: @realxprescheck
Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Investor Relations:
ICR
Raphael Gross
(203) 682-8253
Media
Julie Ferguson
(312) 385-0098
